Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Depreciation & Amortization (CF) (2016 - 2025)

Adma Biologics' Depreciation & Amortization (CF) history spans 13 years, with the latest figure at $2.0 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 5.25% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $8.1 million, up 0.63%, while the annual FY2025 figure was $8.1 million, 0.63% up from the prior year.
  • Depreciation & Amortization (CF) reached $2.0 million in Q4 2025 per ADMA's latest filing, up from $2.0 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $2.1 million in Q1 2024 to a low of $1.2 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $1.9 million, with a median of $2.0 million recorded in 2024.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 55.88% in 2021, then dropped 7.82% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $1.5 million in 2021, then grew by 27.55% to $1.9 million in 2022, then rose by 8.91% to $2.1 million in 2023, then decreased by 7.82% to $1.9 million in 2024, then grew by 5.25% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Depreciation & Amortization (CF) are $2.0 million (Q4 2025), $2.0 million (Q3 2025), and $2.1 million (Q2 2025).